好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cortical Gray Matter Changes in Primary Focal Dystonia
Movement Disorders
P06 - (-)
086
BACKGROUND: Post-mortem and conventional MRI studies suggest primary focal dystonia is not accompanied by structural brain abnormalities. Findings from previous studies using voxel-based morphometry (VBM) reported differences in GM density relative to controls. However, the results were inconsistent among studies.
DESIGN/METHODS: 3D T1-weighted images were obtained from 55 patients with focal dystonia (18 blepharospasm, 19 spasmodic torticollis, 18 writer's cramp) and 36 healthy controls. Patterns of GM density abnormalities in patients relative to controls were assessed using VBM. GM density was correlated with the Blepharospasm Disease Severity scale, Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), and Writer's Cramp Rating Scale (WCRS).
RESULTS: Compared with controls, patients with blepharospasm showed decreased GM in the bilateral precentral (face area) and postcentral gyri, bilateral cerebellum, left frontal inferior operculum, cingulum, lingual gyri, and right hippocampus. In blepharospasm patients, BDS score was associated negatively with the right cingulum GM. Patients with spasmodic torticollis showed decreased GM density in the left rolandic operculum and insula relative to controls. In these patients, the TWSTRS score correlated inversely with right precuneus and cerebellum GM. In patients with writer's cramp, no region of GM difference was found compared with controls, but the WCRS score was negatively associated with left precentral gyrus (arm area) GM. No regions of increased GM density were found in patients relative to controls. No GM differences were found between patient groups.
CONCLUSIONS: Patients with blepharospasm and spasmodic torticollis exhibit GM volume differences in cortical regions highly relevant to motor network and sensory processing and cognitive modulation of motor behavior. Cortical abnormalities detected by VBM may contribute to the clinical features of focal dystonia.
Authors/Disclosures
Lidia Sarro, MD (Ospedale San Raffaele)
PRESENTER 		No disclosure on file
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Alexandra Tomic No disclosure on file
No disclosure on file
Francesca Caso, MD (Universita' Vita Salute San Raffaele) Dr. Caso has nothing to disclose.
No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of 好色先生, Science and Technological Development of Serbia.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School) Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.